Depressive Spectrum Disorders in Cancer: Diagnostic Issues and Intervention. A Critical Review

Rosangela Caruso1,2 · Maria Giulia Nanni1,2 · Michelle B. Riba3,4,5 · Silvana Sabato1 · Luigi Grassi1,2

Published online: 9 May 2017
© The Author(s) 2017. This article is an open access publication

Abstract Depressive spectrum disorders, including major depression, persistent depression, minor and sub-syndromal depression, and other forms of depressive conditions, such as demoralization, are among the most common psychiatric consequences of cancer patients, affecting up to 60% of patients. In spite of the negative effects and the burden for cancer patients and their families, these disorders often remain unrecognized and undertreated. The present review aims at summarizing the relevant data concerning the diagnostic challenges within the depressive spectrum disorders among cancer patients. Also, the most relevant data relative to integrated intervention, including psychopharmacological and psycho-social treatment, for depression in cancer patients are critically evaluated. It is mandatory that health care professionals working in oncology (e.g., oncologists, surgeons, radiation oncologists, primary care physicians, nurses, social workers, psychologists) receive training in the diagnosis and integrated management of the different types of disorder within the spectrum of clinical depression.

Keywords Psychiatry · Depression · Cancer · Psychopharmacology · Antidepressants · Psychotherapy

Introduction

Depression is one of the most common psychiatric disorders in cancer patients [1, 2•]. An extremely vast literature has examined several issues related to depression including its prevalence, with data showing that 25–30% of cancer patients suffer from depressive disorders (percentages ranging from 4 to 60%); [3] the most important risk factors, including biological, psychological, and social factors; and the most effective and valid methods to correctly screen and assess depression in cancer, including short (and ultra-short) tools, self-report questionnaires, and semi-structured interviews [4••]. Depression has been shown to have negative consequences on both the patient and family with data indicating a role of this clinical condition in reducing adherence to treatments, in increasing subjective perception of physical symptoms and, possibly, in worsening prognosis [5, 6•].

Yet depression in cancer patients still remains quite often undetected in clinical practice with studies indicating that in general 50–60% of depressed cancer patients are not properly recognized [7]. Among elderly people, in whom the incidence of both depression and cancer is higher, this problem is even more evident [8]. As reported by Greenberg [9], cultural, stigma, and organizational issues continue to represent an obstacle in the delivery of mental health interventions in cancer settings. It has been reported that communication is also a problem, with...
a very low proportion of patients discussing their low mood with their doctors or oncologists and choosing to address somatic rather than affective and emotional symptoms [9]. Diagnostic issues are an important cause of under-recognition. In fact, the term “depression” indicates a large-spectrum of conditions, ranging from a transient normal feeling in response to an adverse event, to a highly severe and impairing syndrome. Thus, the concept of depressive spectrum disorders seems to be more appropriate to address the different manifestations of clinical depression, including major depression, persistent depression, minor and sub-syndromal depression, and other forms of depressive conditions, such as demoralization [4••]. Thinking in terms of a spectrum may also help clinicians to be more sensitive to the different forms of depressive conditions in the different phases of the cancer trajectory, and to be more precise in planning proper intervention.

With this background, the aims of the present critical review are (i) to summarize the diagnostic challenges within the depressive spectrum disorders among cancer patients and (ii) to report the most relevant data relative to integrated intervention, including psychosocial and psychopharmacological treatment, for depression in cancer patients. For these purposes, a search was made of the major databases over the last 15 years (Embase/Medline, PsycLIT, PsycINFO, the Cochrane Library) from January 2001 to June 2016 by including the most relevant studies in full journal articles that investigated the problem of diagnosis and treatment of depression in patients with cancer. Studies published in conference proceedings, qualitative research, commentaries and discussions, letters, books, book chapters, or research not published in the English language were excluded.

Diagnostic Issues

The appropriate criteria for recognizing and diagnosing depression in cancer patients have been extensively debated over the last years [10, 11]. In cancer settings, it is important to differentiate the types and forms of depression, according to the most commonly used systems in nosology, namely the International Classification of Diseases (ICD) and the Diagnostic and Statistical Manual of Mental Disorders (DSM).

Major Depression

Major depression is arguably the most severe form of depressive syndromes, affecting about 7% of the general population (8–9% of female and 3–4% of men), with data in oncology indicating a prevalence between 15 and 40%, depending on several factors (e.g., type, stage of cancer, in/outpatient, on/off treatment, type of diagnostic tool for depression) [2•]. A significant problem underlined by a number of authors over the last 35 years is that many symptoms of depression, such as loss of appetite, loss of weight, insomnia, cognitive impairment, fatigue, and loss of energy, may be a consequence of cancer or cancer treatment rather than depression itself. Therefore the debate regarding the need to modify the DSM criteria of major depression when applied to cancer (e.g., [12, 13]) has grown with different opinions and several proposals suggested, namely: to include all the symptoms irrespective of the fact that these symptoms may or may not be attributable to cancer (inclusive approach), to replace somatic symptoms with cognitive-affective items (substitute approach), to add some new affective symptoms to the original criteria (alternative approach), and to exclude somatic symptoms and use only affective symptoms to make the diagnosis (exclusive approach) [14•] (Table 1). In a study of 728 cancer patient with major depression, Akechi et al. [15] showed that the somatic symptoms (apetite loss, weight loss, insomnia, fatigue, loss of energy, and diminished ability to think or concentrate), feelings of worthlessness, and suicidal ideation were not useful, among the DSM-IV criteria, for diagnosing and/or judging the severity of depression among cancer patients. Two other alternative criteria (“not participating in medical care in spite of ability to do so, not progressing despite improving medical condition and/or in functioning at a lower level than the medical condition warrants”; “social withdrawal or decreased talkativeness”) showed to be useful markers of the severity of major depression among cancer patients, suggesting the need for a two-step diagnostic approach (inclusive criteria plus two alternative criteria). More recent data, however, indicate that many somatic symptoms remain influential when diagnosing major depression in the context of cancer, with scoring-method not excluding somatic symptoms having the greatest effect on assessment outcomes [16]. In palliative care, in particular, the need to have a clear-cut framework to assess depression has frequently been balanced with the need to focus on clinical utility and evaluation of symptoms and depressive syndromes rather than on a specific diagnosis, such as major depression [17, 18]. However, in a recent study involving 969 patients with advanced cancer within the European Palliative Care Research Collaborative-Computer Symptom Assessment Study (EPCRC-CSA) [19••], it has been shown that the prevalence of depression changed according to the scoring-methods used, specifically inclusive (algorithm scoring including the somatic symptom-criteria, rate 13.7%), exclusive (algorithm scoring excluding the somatic symptom-criteria, rate 14.9%), and sum-score (sum of all symptoms of the Patient Health Questionnaire cut-off ≥8, rate 45.3%). The scoring-method, not excluding somatic symptoms, had the greatest effect on assessment outcomes, since depression was significantly associated with pain and lower performance status. Also, regarding the survivorship
Table 1: Proposals for the diagnosis of major depression in cancer patients [12, 13, 15]

| Proposal | Details |
|----------|---------|
| Etiologic approach (ICD-DSM): | based on the nine traditional symptoms of major depression (depressed mood, anhedonia, appetite or weight change, sleep disturbance, fatigue, psychomotor disturbance, feelings of worthlessness or guilt, impaired concentration, and suicidal thoughts) to be present (at least five—of which either depressed mood or anhedonia are mandatory—for at least 2 weeks of duration), but symptoms that are clearly and fully attributable to the cancer (as a general medical condition) are excluded, otherwise depression due to a general medical condition is diagnosed. |
| Inclusive approach (modified ICD-DSM): | as above, but symptoms are counted regardless whether or not they might be attributable to cancer. |
| Substitutive approach (Endicott’s criteria) [12]: | in Criterion A, neurovegetative/somatic symptoms are substituted by cognitive/affective symptoms (specifically: diminished ability to think or concentrate or indecisiveness replaced by fearfulness or depressed appearance in face or body posture; weight loss or gain or a decrease in appetite replaced by social withdrawal or decreased talkativeness; insomnia or hypersomnia replaced by brooding, self-pity or pessimism; fatigue or loss of energy replaced by “cannot be cheered up, doesn’t smile, no response to good news or funny situations). These substitute symptoms should be used if the medical condition is likely to affect/cause the somatic symptoms. |
| Exclusive approach (Cavanaugh’s criteria) [13]: | in Criterion A, hopelessness, helplessness, and not caring anymore are added to either depressed mood or anhedonia as mandatory (plus three other symptoms) for at least 2 weeks of duration; significant weight loss or weight gain, psychomotor agitation or retardation, insomnia or hypersomnia, and fatigue or loss of energy are excluded, unless temporarily related to cognitive/affective symptoms. In Criterion B, one extra item (not participating in medical care, in spite of ability to do so, he is not progressing despite improved medical condition and/or is functioning at a lower level than the medical condition warrant) is added. |
| Alternative approach (Akechi’s criteria) [15]: | as in inclusive approach plus other items do be fulfilled in order to diagnose mild major depressive episode (fearfulness or depressed appearance in face or body posture; brooding, self-pity or pessimism), moderate major depressive episode (not participating in medical care in spite of ability to do so, not progressing despite improved medical condition and/or in functioning at a lower level than the medical condition warrants; social withdrawal or decreased talkativeness) and severe major depressive episode (cannot be cheered up, doesn’t smile, no response to good news or funny situations). |

Inclusive approach (modified ICD-DSM): as above, but symptoms are counted regardless whether or not they might be attributable to cancer. Substitutive approach (Endicott’s criteria): in Criterion A, neurovegetative/somatic symptoms are substituted by cognitive/affective symptoms (specifically: diminished ability to think or concentrate or indecisiveness replaced by fearfulness or depressed appearance in face or body posture; weight loss or gain or a decrease in appetite replaced by social withdrawal or decreased talkativeness; insomnia or hypersomnia replaced by brooding, self-pity or pessimism; fatigue or loss of energy replaced by “cannot be cheered up, doesn’t smile, no response to good news or funny situations). These substitute symptoms should be used if the medical condition is likely to affect/cause the somatic symptoms. Exclusive approach (Cavanaugh’s criteria): in Criterion A, hopelessness, helplessness, and not caring anymore are added to either depressed mood or anhedonia as mandatory (plus three other symptoms) for at least 2 weeks of duration; significant weight loss or weight gain, psychomotor agitation or retardation, insomnia or hypersomnia, and fatigue or loss of energy are excluded, unless temporarily related to cognitive/affective symptoms. In Criterion B, one extra item (not participating in medical care, in spite of ability to do so, he is not progressing despite improved medical condition and/or is functioning at a lower level than the medical condition warrant) is added. Alternative approach (Akechi’s criteria): as in inclusive approach plus other items do be fulfilled in order to diagnose mild major depressive episode (fearfulness or depressed appearance in face or body posture; brooding, self-pity or pessimism), moderate major depressive episode (not participating in medical care in spite of ability to do so, not progressing despite improved medical condition and/or in functioning at a lower level than the medical condition warrants; social withdrawal or decreased talkativeness) and severe major depressive episode (cannot be cheered up, doesn’t smile, no response to good news or funny situations). |

In spite of the high prevalence of adjustment disorders in cancer settings (20-25%) [3, 24], the diagnostic features and the clinical utility of diagnosing these disorders with both depressed mood or mixed features (anxiety and depression) in cancer, as well as in medically ill patients in general, have been repeatedly questioned. The main characteristics of adjustment disorder and its sub-types have been reported to be vague and imprecise to have any clinical utility, particularly in oncology [25–27]. The lack of guidance on the distinction from normal to abnormal stress reactions; plus the lack of specific diagnostic criteria in terms of symptom numbers, behavioral parameters, or their combinations; and the inadequate operationalization to distinguish adjustment from adaptation, socialization, and coping have been reported [28, 29]. Although the criteria were proposed to be slightly modified in cancer settings [13] (Table 2) and although in the DSM-5 the disorder is now classified under the chapter of Trauma and Stress-Related Disorders, its definition and diagnostic criteria are still criticized [30]. By examining patients with the diagnosis of adjustment disorders and major depression, it has been reported that many different sub-types (e.g., adjustment disorders with features of alexithymia, major depression with irritable mood) are possible in medically ill, including cancer patients, but this does not mean that all these phenomenological conditions are separate and represent specific diagnoses [31, 32]. For the same reasons, the DSM-5 and ICD-10 categorical distinction between minor depression, mixed anxiety-depressive disorders, and brief recurrent depressive episodes, based on quite debatable criteria, are also not particularly useful in cancer and palliative care settings, where the duration of suffering, the impact of the stress represented by cancer and treatment, and the intensity of depressive symptoms may fluctuate and cannot be represented by restrictive categorical
Demoralization syndrome (Kissane et al.) [36, 37] (criteria A and B are required; criterion C is a specifier for the presence of hopelessness)

Demoralization/subjective incompetence (De Figueiredo) [34]
A combination of distress (anxiety, sadness, discouragement, and resentment) and subjective incompetence (a feeling of being trapped or blocked because of a sense of inability to plan and initiate concerted action toward one or more goals)

Persistent failure of coping with internally or externally induced stress
Feelings of impotence, isolation, and despair
Individual’s self-esteem damaged
Feelings of rejection by others because of his or her failure to meet their expectations

Diagnostic Criteria for Psychosomatic Research (DCPR Criteria)— demoralization module (Fava et al.) [35]
A. A feeling state characterized by the patient’s consciousness of having failed to meet his or her own expectations (or those of others) or being unable to cope with some pressing problems; the patient experiences feelings of helplessness, or hopelessness, or giving up
B. The feeling state should be prolonged and generalized (duration of at least 1 month)
C. The feeling closely antedated the manifestations of a medical disorder or exacerbated its symptoms

DCPR Criteria - demoralization module -Revised (Fava et al.) [38-4]
A. A feeling state characterized by the perception of being unable to cope with some pressing problems and/or of lack of adequate support from others (helplessness); the individual maintains the capacity to react
B. The feeling state is prolonged and generalized (duration of at least 1 month)
C. A feeling state characterized by the consciousness of having failed to meet expectations associated with the conviction that there are no solutions for current problems and difficulties (hopelessness)

[criteria A and B are required; criterion C is a specifier for the presence of hopelessness]

Demoralization/subjective incompetence (De Figueiredo) [34]
A combination of distress (anxiety, sadness, discouragement, and resentment) and subjective incompetence (a feeling of being trapped or blocked because of a sense of inability to plan and initiate concerted action toward one or more goals)

Persistent failure of coping with internally or externally induced stress
Feelings of impotence, isolation, and despair
Individual’s self-esteem damaged
Feelings of rejection by others because of his or her failure to meet their expectations

Demoralization syndrome (Kissane et al.) [36, 37]

Encompassing hopelessness or loss of meaning and purpose in life
Cognitive attitudes of pessimism, helplessness, sense of being trapped, personal failure
Absence of drive or motivation to cope differently
Associated features of social alienation or isolation and lack of support
Fluctuation in emotional intensity
Persistence of above-mentioned phenomena across two or more weeks (and a major depressive or other psychiatric episode should not be present as the primary condition)

including oncology, was demonstrated to be 30.4%, while major depression (according to the DSM-IV) was present in 16.7% of the patients [39, 40]. Similar data were reported in a study of 721 patients with severe medical illness, including advanced cancer [41]. Demoralization has been shown to have a negative impact on cancer patients, such as poorer quality of life and higher levels of worries and preoccupation related to cancer (e.g., the illness itself, feeling different from others, the impact on sexual life), [42] loss of dignity, [43], and suicidal ideation [44]. Several recent systematic reviews on this topic are available [45, 46].
47] and confirm the importance of this syndrome in medical and oncology settings [48].

Intervention

Intervention for depressive spectrum disorders has been examined in a number of studies, with several reviews and meta-analyses available. Some of them concentrate attention only on the proper use of psychotropic drugs, including antidepressants (ADs) and/or adjuvant drugs [49•, 50••, 51•], some only on psychological and psychotherapy interventions [52••], and some on both [53–56]. It is actually the integration of these two forms of intervention, as the definition of “PsychopharmOncology” [47] indicates, that is important to be considered in the care of cancer patients.

Psychopharmacological Intervention

According to psychopharmacological studies, there is evidence that ADs are more effective than placebo in both cancer patients with major depression or depressive symptoms and in those with other cancer-related distressing symptoms (see [49•,50••,51•] for specific reviews and [57, 58]). Their efficacy is positively associated with length of treatment, and no difference has been reported between ADs and placebo in terms of overall acceptability [59•, 60]. The data regarding the use of ADs in cancer patients is however quite poor for several reasons, such as lack of RCTs, high number of uncontrolled clinical trials, lack of longer follow-up period (more than 12 weeks), imprecision arising from small sample sizes and wide confidence intervals, and inconsistency due to statistical or clinical heterogeneity [52••].

It is also a fact that a high number of cancer patients with depression did not receive proper antidepressant treatment. A recent review of prescriptions of ADs in oncology indicate that there is considerable variation in the prescribing patterns across the world, with only few studies reporting robust data on exact dose or follow-up regimens [61••]. This confirms recent reports by Walker et al. [62••] showing that 1,130 (73%) out of 1,538 patients with depression were not receiving effective treatment, and by Fisch et al. [63•] showing that among 3,106 ambulatory patients with cancer, only one fourth of those with depression were treated with ADs. Also, a further German study showed that a lower proportion of cancer patients with depression had received ADs (66.5%) in comparison with a control group of patients with only depression (72.8%) [64]. There are also variables influencing the prescription of ADs, including gender (females > men), ethnicity (Caucasians receiving more SSRIs than other ethnic groups), and treatment (> in patients with extensive cancer treatment) [56, 65, 66]. In contrast with these data, however, a different study carried out in Australia indicated that newest ADs were more commonly prescribed in cancer populations, particularly if in an advanced phase of illness, than in cancer-free populations [67].

Psychosocial Intervention

With regard to psychosocial intervention, an extremely high number of studies, meta-analyses, and reviews exist. The types of psychotherapy approaches in cancer patients with depression are vast (from cognitive-behavior therapy to existential-based intervention, from psychodynamically oriented therapy to educational, relaxation, expressive-supportive therapy, and other forms of treatment, such as mindfulness), supporting the view that it is more important to focus on participants’ variables (e.g., level of depressive symptoms, type and stage of cancer, personality variables) [68] rather than the type of intervention itself [69, 70]. For example, a systematic review [71] examining 199 potential papers, of which a total of 20 studies were selected and involved 3,340 heterogeneous cancer patients, showed that cancer patients who had the greater benefit from intervention were those who reported low levels of optimism and neuroticism; high levels of emotional expressiveness, interpersonal sensitivity, and dispositional hypnotisability; and poorer quality of life, interpersonal relationships, and sense of control.

The effectiveness of psychosocial interventions for cancer patients was shown to be related to many different variables, including the type of participants (e.g., cancer type and stage, inpatients or outpatients), the mode of delivery of the intervention (e.g., face-to-face, telephone psychological support), and the discipline of the therapist (e.g., nurses with training in psycho-education, psychologists) [72]. However, among advanced cancer patients with depression, a Cochrane review by Akechi et al. [73] indicated that there is evidence from randomized controlled trials (RCTs) suggesting that psychotherapy is useful for treating depressive states, although there is a lack of specific studies examining the effectiveness of psychotherapy for patients with clinically diagnosed depression.

This many-sided scenario has determined some inconsistencies in the reported effects of psychosocial intervention, with authors emphasizing its significant benefits [74–77], and others suggesting to be more cautious in examining the results of the studies available [78, 79]. Also, disagreement exists about the format of psychotherapy, with some authors underlining the superiority of individual treatments versus group therapy [80], and others suggesting the equivalence in
efficacy of individual and group psychotherapy [81]. In a systematic review of 14 published meta-analyses, Linden and Girgis [82] underscored that treatment effects are consistently positive but also vary greatly in magnitude, even if there is no evidence for differential treatment effects for different cancer types and stages. More recently, in a vast review analyzing 98 studies (covering 22,238 patients) with 218 treatment-control comparisons, Faller et al. [48] observed a significant small-to-medium effect for individual and group psychotherapy and psycho-education, with effects sustained in the medium term (≤6 months) and long term (>6 months).

Less data are available regarding the efficacy of psychosocial intervention in demoralization, although some recent RCTs in patients with both advanced and non-stages of illness indicate that a meaning-oriented and dignity-oriented therapy significantly reduce demoralization scores and improve psychosocial functioning [83••, 84, 85].

Integrated Approaches

The need for the integration of psychosocial and pharmacological intervention within specific programs has also emerged in the last years [86]. A review relative to 10 studies involving 1,362 severely depressed cancer patients with mixed cancer types and stages confirmed that integrated psychological and pharmacologic approaches are effective but should be targeted productively toward cancer patients with elevated depressive symptoms in order to maximize effectiveness, accessibility, and integration into clinical care [87]. Significant benefits in terms of outcome and cost-effectiveness have been shown in a recent series of studies within the Depression Care for People with Cancer (DCPC) program in the Symptom Management Research Trials (SMaRT) Oncology randomized controlled trials carried out in Scotland [88–90]. More specifically, in one study [91••] that enrolled 500 participants of whom 253 were randomly allocated to the DCPC program and 247 to usual care (UC), response to treatment was higher among the former than the latter (62% vs. 17%). Patients in the DCPC program had less depression, anxiety, pain, and fatigue and better functioning, health, quality of life, and perceived quality of depression care than patients in UC. In a further study, the same authors [92] confirmed their results when examining the efficacy of the DCPC program in the management of depression in lung cancer patients compared with UC. A recent report updating the Cancer Care Ontario Program, an Evidence-Based Care guideline [93•] for the management of depression in adult patients with cancer, specifically has focused on integrating practical management tools to assist clinicians in delivering appropriate treatments for depression in patients with cancer by covering pharmacologic, psychological, and collaborative care interventions. More recently, the same group [94••] has confirmed that a collaborative care model that incorporates a stepped care approach is recommended with multidisciplinary mental health care restructuring be required for optimal management of depression.

Conclusions

Depressive spectrum disorders in cancer patients should be taken into serious consideration since in patients with medical diseases, depression has the largest effect on worsening mean health scores and on increasing disability compared with the other chronic conditions [95]. However, the several clinical and phenomenological aspects of depressive disorders should be re-examined and recognized in terms of “spectrum” in order to screen the patients in a more specific way and to reach a more reliable diagnosis which makes referral and intervention more appropriate.

Recent consensus guidelines, algorithms, and reviews have been developed and proposed in the hope to promote integrated psychopharmacological and psychosocial treatment [96–99] in order to reduce the burden of psychiatric morbidity on both the patient and the family [100].

Thus, it is mandatory that health care professionals working in oncology, such as oncologists, surgeons, radiation oncologists, primary care physicians, nurses, social workers, and psychologists, receive training in the diagnosis and management of depressive spectrum disorders, given the different intervention approaches according to the type of depressive disorder [101, 102].

It has to be stressed that cancer patients with depression have been reported to have a low rate of utilization of mental health services [103–106], although some improvement has been recently underscored in some countries such as the USA [107]. In many other countries, significant disparities and inequalities still exist as far as psychosocial care of cancer patients is concerned [108, 109••].

Therefore, more research and more efforts in the development of psycho-oncology services and in integration of mental health in oncology are necessary in cancer and palliative care settings.

Acknowledgements This paper was supported by the University of Ferrara Research Funding (FAR). LG, MGN, RC and SS would like to express their gratitude to Unitalsi Triveneta and the Italian Medical Board/Association – Section of Ferrara for their unrestricted research grant and support in memory of Francesco Tomasi, MD, and the Associazione per Supporto Psico-Oncologico (ASPO) for their unrestricted clinical research grant for the improvement of psychosocial care in oncology.

Compliance with Ethical Standards

Conflict of Interest Rosangela Caruso, Maria Giulia Nanni, Silvana Sabato, declare that they have no conflict of interest.
Michelle B. Riba is on the editorial board of Current Psychiatry Reports as the editor of a section and receives money for this work. Dr. Riba recuses herself from the review of this paper. Dr. Riba also has edited books on psycho-oncology for which she receives royalties. Dr. Grassi has edited books on psycho-oncology for which he receives royalties.

**Human and Animal Rights and Informed Consent** This article does not contain any studies with human or animal subjects performed by any of the authors.

**References**

Papers of particular interest, published recently, have been highlighted as:

- Of major importance
- Of major importance

1. Smith H. Depression in cancer patients: pathogenesis, implications and treatment. Oncol Lett. 2015;9:1509–14.
2. Dauchy S, Dolbeault S, Reich M. Depression in cancer patients. European Journal of Cancer Suppl. 2013;11:205–15. This is a review of the most important aspects of depression in cancer, including pathogenesis and treatment.
3. Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis. Lancet Oncol. 2011;12:160–74.
4. Caruso R, Nanni MG, Riba M, Sabato S, Mitchell A, Croce E, Grassi L. Depressive spectrum disorders in cancer: prevalence, risk factors and screening. A critical review Acta Oncologica. 2017:56:146–55. This is a very updated critical review of reviews and meta-analyses related to the epidemiology of depression, the risk factors, and the screening and assessment methods for depressive spectrum disorders in cancer patients.
5. Grassi L, Berardi MA, Ruffilli F, Meggiolaro E, Andritsch E, Sirgo A, Caruso R, Juan Linares E, Bellé M, Massarenti S, Nanni MG; IOR-IRST Psycho-Oncology and UniFE Psychiatry Co-Authors.: Role of psychosocial variables on chemotherapy-induced nausea and vomiting and health-related quality of life among cancer patients: a European study Psychother Psychosom. 2015;84(6):339–47.
6. Sotelo JL, Musselman D, Nemeroff C. The biology of depression in cancer and the relationship between depression and cancer progression. Int Rev Psychiatry. 2014;26(1):16–30. This article describes and analyzes the most important pathways psychobiological relating depression with progression of cancer.
7. Grassi L, Nanni MG, Caruso R. Emotional distress in cancer: screening policy, clinical limitations, and educational needs. Journal of Medicine and the Person. 2010;8:51–9.
8. Spoletini I, Gianni W, Repetto L, Bria P, Cellagione C, Bossù P, Spalletta G. Depression and cancer: an unexplored and unresolved emerging issue in elderly patients. Crit Rev Oncol Hematol. 2008;65:143–55.
9. Greenberg DB. Barriers to the treatment of depression in cancer patients. J Natl Cancer Inst Monogr. 2004;32:127–35.
10. Mitchell AJ. Are one or two simple questions sufficient to detect depression in cancer and palliative care? A Bayesian meta-analysis. Br J Cancer. 2008;98:1934–43.
11. Mitchell AJ, Meader N, Davies E, Clover K, Carter GL, Lосsalzo MJ, Linden W, Grassi L, Johansen C, Carlson LE, Zabora J. Meta-analysis of screening and case finding tools for depression in cancer: evidence based recommendations for clinical practice on behalf of the Depression in Cancer Care consensus group. J Affect Disord. 2012;140(2):149–6.
12. Endicott J. Measurement of depression in patients with cancer. Cancer. 1984;53(10 Suppl):2243–9.
13. Cavannaugh SV. Depression in the medically ill. Critical issues in diagnostic assessment. Psychosomatics. 1995;36:48–59.
14. Guan NC, Sulaíman AH, Zainal NZ, Boks MP, De Wit NJ. Diagnostic criteria for major depressive disorder in cancer patients: a review. Int J Psychiatry Med. 2013;45:73–82. This is an exploration of the different criteria for major depression in cancer, indicating that there is no standard reference test and precise definition of alternative criteria in literature studies and recognized diagnostic criteria for depression in cancer patients despite an apparent need for such criteria.
15. Akechi T, Ietsugu T, Sukigara M, Okamura H, Nakano T, Akizuki N, Okamura M, Shimizu K, Okuyama T, Furukawa TA, Uchitomi Y. Symptom indicator of severity of depression in cancer patients: a comparison of the DSM-IV criteria with alternative diagnostic criteria. Gen Hosp Psychiatry. 2009;31:225–32.
16. Mitchell AJ, Lord K, Symonds P. Which symptoms are indicative of DSMIV depression in cancer settings? An analysis of the diagnostic significance of somatic and non-somatic symptoms. J Affect Disord. 2012;138(1–2):137–48.
17. Reeve J, Lloyd-Williams M, Dowrick C. Revisiting depression in palliative care settings: the need to focus on clinical utility over validity. Palliat Med. 2008;22(4):383–91.
18. Wasteson E, Brenne E, Higginson IU, Hotopf M, Lloyd-Williams M, Kaasa S. Loge JH; European Palliative Care Research Collaborative (EPCRC). Depression assessment and classification in palliative cancer patients: a systematic literature review. Palliat Med. 2009;23(8):739–53.
19. Lie HC, Hjermstad MJ, Fayers P, Finset A, Kaasa S, Loge JH. European Palliative Care Research Collaborative (EPCRC). Depression in advanced cancer—assessment challenges and associations with disease load. J Affect Disord. 2015;173:176–84. This is a large European study examining the effect of different scoring-methods of depressive symptoms on detecting depression, and the relationship between disease load and depression amongst patients with advanced cancer.
20. Zhao G, Okoro CA, Li J, White A, Dhingra S, Li C. Current depression among adult cancer survivors: findings from the 2010 Behavioral Risk Factor Surveillance System. Cancer Epidemiol. 2014;38(6):757–64. This is an important and large study of depression among cancer survivors, indicating the need for close monitoring of depressive symptoms even in patients recovered from cancer.
21. Rheberman D, Graham R. The re-labelling of dysthymic disorder to persistent depressive disorder in DSM-5: old wine in new bottles? Curr Opin Psychiatry. 2014;27:27–31.
22. Wagner LI, Pugh SL, Small Jr W, Kirshner J, Sidhu K, Bury MJ, DeNittis AS, Alpert TE, Tran B, Bloom BF, Mai J, Yeh A, Sarma K, Becker M, James J, Bruner DW. Screening for depression in cancer patients receiving radiotherapy: feasibility and identification of effective tools in the NRG oncology RTOG 0841 trial. Cancer. 2017;123(3):485–93.
23. Osório FL, Lima MP, Chagas MH. Screening tools for psychiatry disorders in cancer setting: caution when using. Psychiatry Res. 2015;229(3):739–44. This is a large study of 1384 patients who responded to several self-assessment instruments of whom 400 were interviewed by telephone to confirm the presence/absence of psychiatric diagnosis, with ROC analyses showing different levels of specificity and suggesting that sensitivity indicators should be used with caution in the cancer clinical setting.
24. Grassi L, Sabato S, Rossi E, Marmi L, Biancosino B. Affective syndromes and their screening in cancer patients with early and
stable disease: Italian ICD-10 data and performance of the distress thermometer from the southern European psycho-oncology study (SEPOS). J Affect Disord. 2009;114(1–3):193–9.

25. Casey P. Adult adjustment disorder: a review of its current diagnostic status. J Psychiatr Pract. 2001;7(1):32–40.

26. Casey P, Dowrick C, Wilkinson G. Adjustment disorders: fault line in the psychiatric glossary. Br J Psychiatry. 2001;179:479–81.

27. Baumeister H, Kufner K. It is time to adjust the adjustment disorder category. Curr Opin Psychiatri. 2009;22:409–12.

28. Baumeister H, Maercker A, Casey P. Adjustment disorder with depressed mood: a critique of its DSM-IV and ICD-10 conceptualisations and recommendations for the future. Psychopathology. 2009;42(3):139–47.

29. Israelashvili M. Should adjustment disorder be conceptualized as transitional disorder? In pursuit of adjustment disorders definition. J Ment Health. 2012;21(6):579–88.

30. Casey P. Adjustment disorder: new developments. Curr Psychiatry Rep. 2014;16(6):451.

31. Grassi L, Mangelli L, Fava GA, Grandi S, Ottolini F, Porcelli P, Rafanelli C, Rigatelli M, Sonino N. Psychosomatic characterization of adjustment disorders in the medical setting: some suggestions for DSM-V. J Affect Disord. 2007;101(1–3):251–4.

32. Guidi J, Fava GA, Picardi A, Porcelli P, Bellomo A, Grandi S, Grassi L, Pasquini P, Quaresmet R, Rafanelli C, Rigatelli M, Sonino N. Subtyping depression in the medically ill by cluster analysis. J Affect Disord. 2011;132(3):383–8.

33. Grassi L, Biancosino B, Marmai L, Rossi E, Sabato S. Psychological factors affecting oncology conditions. Adv Psychosom Med. 2007;28:57–71.

34. de Figueiredo JM. Depression and demoralization: phenomenologic differences and research perspectives. Compr Psychiatry. 1993;34(5):308–11.

35. Fava GA, Freyberger HJ, Bech P, Christodoulou G, Sensky T, Bech P, Buckland C, Fava GA, Picardi A, Porcelli P, Bellomo A, Grandi S, Grassi L, Pasquini P, Quaresmet R, Rafanelli C, Rigatelli M, Sonino N. Subtyping depression in the medically ill by cluster analysis. J Affect Disord. 2007;114(1–3):251–4.

36. Clarke DM, Kissane DW. Demoralization: its phenomenology and importance. Australian and New Zealand Journal of Psychiatry. 2002;36(6):733–42.

37. Kissane DW, Clarke DM, Street AF. Demoralization syndrome—a relevant psychiatric diagnosis for palliative care. J Palliat Care. 2001;17(1):12–21.

38. Fava GA, Cosci F, Sonino N. Current Psychosomatic Practice. Psychother Psychosom. 2013;82(1):13–30. This important paper presents and updates revising the criteria for the clusters of psychosocial dimensions, including demoralization, common in medically ill patients and not detected by the ICD or nosology.

39. Mangelli L, Fava GA, Grandi S, Grassi L, Ottolini F, Porcelli P, Rafanelli C, Rigatelli M, Sonino N. Assessing demoralization and depression in the setting of medical disease. J Clin Psychiatry. 2005;66(3):391–4.

40. Grassi L, Sabato S, Rossi E, Biancosino B, Marmai L. The use of the Diagnostic Criteria for Psychosomatic Research (DCPR) in oncology. Psychother Psychosom. 2005;74:100–7.

41. Clarke DM, Kissane DW, Trauer T, Smith GC. Demoralization, anhedonia and grief in patients with severe physical illness. World Psychiatry. 2005;4:96–105.

42. Grassi L, Rossi E, Sabato S, Cruciani G, Zambelli M. Diagnostic Criteria for Psychosomatic Research (DCPR) and psychosocial variables in breast cancer patients. Psychosomatics. 2004;45:483–91.

43. Vehling S, Mehnert A. Symptom burden, loss of dignity, and demoralization in patients with cancer: a mediation model. Psychooncology. 2014;23:283–90.

44. Fang CK, Chang MC, Chen PJ, Lin CC, Chen GS, Lin J, Hsieh RK, Chang YF, Chen HW, Wu CL, Lin KC, Chiu YJ, Li YC. A correlational study of suicidal ideation with psychological distress, depression, and demoralization in patients with cancer. Support Care Cancer. 2014;22:3165–74.

45. Tecuta L, Tomba E, Grandi S, Fava GA. Demoralization: a systematic review on its clinical characterization. Psychol Med. 2015;45:673–91. This is a comprehensive review of the instruments to assess the prevalence rates of demoralization, evidence of discriminant validity from major depression, factors associated with demoralization and evidence of clinical utility.

46. Robinson S, Kissane DW, Brooker J, Burney S. A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: a decade of research. J Pain Symptom Manag. 2015;49:595–610. This review summarizes the studies showing that demoralization is prevalent in patients with progressive disease or cancer (13–18%) with a range of factors consistently associated with the syndrome, including poorly controlled physical symptoms, inadequately treated depression and anxiety, reduced social functioning, unemployment, and single status.

47. Tang PL, Wang HH, Chou FH. A systematic review and meta-analysis of demoralization and depression in patients with cancer. Psychosomatics. 2015;56(6):634–43.

48. Grassi L, Nanni MG. Demoralization syndrome: new insights in psychosocial cancer care. Cancer. 2016;122(14):2130–3.

49. Caruso R, Grassi L, Nanni MG, Riba M. Psychopharmacology in psycho-oncology. Curr Psychiatry Rep. 2013;15(9):393. This is a review of studies examining the several medication types to be used in the treatment of psychiatric and cancer-related symptoms stemming from the disease itself and/or its treatment, including sleep disturbance, loss of appetite, neuropsychic pain, nausea, fatigue, and hot flashes.

50. Grassi L, Caruso R, Hammele K, Nanni MG, Riba M. Efficacy and safety of psychotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int Rev Psychiatry. 2014;26(1):44–62. This review explores a comprehensive way the several factors affecting the use of psychotropic drugs in cancer care, specifically pharmacokinetics and pharmacodynamics, interaction, safety, side effects, and efficacy in the integrated and multidimensional approach to cancer patients treated in different settings.

51. Thekdji SM, Trinidad A, Roth A. Psychopharmacology in cancer. Curr Psychiatry Rep. 2015;17(1):529. This is a review of studies examining the several medications types to be used in the treatment of psychiatric and cancer-related symptoms.

52. Faller H, Schuler M, Richard M, Heckl U, Weis J, Küffner R. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol. 2013;31(6):782–93. This review and metaanalysis analyzes the efficacy of the several forms of psychological intervention in cancer in 198 studies (covering 22,238 patients) reporting 218 treatment-control comparisons. The "duration of the intervention” had a moderator effect, with longer interventions producing more sustained effects.

53. Fisch M. Treatment of depression in cancer. J Natl Cancer Inst Monogr. 2004;32:105–11.

54. Rodin G, Lloyd N, Katz M, Green E, Mackay JA, Wong RK, Faller H, Schuler M, Richard M, Heckl U, Weis J, Küffner R. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol. 2013;31(6):782–93. This review and meta-analysis evaluates the efficacy of the several forms of psychological intervention in cancer in 198 studies (covering 22,238 patients) reporting 218 treatment-control comparisons. The “duration of the intervention” had a moderator effect, with longer interventions producing more sustained effects.

55. Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer. 2006;94:372–90.

56. Li M, Fitzgerald P, Rodin G. Evidence-based treatment of depression in patients with cancer. J Clin Oncol. 2012;30(11):1187–96.
57. Laoutidis ZG, Mathiak K. Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry. 2013;13:140.

58. Riblet N, Larson R, Watts BV, Holztheimer P. Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2014;36(5):466–73.

59. Ostuzzi G, Matcham F, Dauchy S, Barbuti C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2015;1(6):CD011006. General review of the randomized trials of the use of antidepressants in cancer care.

60. Ostuzzi G, Benda L, Costa E, Barbuti C. Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: systematic review and meta-analysis. Cancer Treat Rev. 2015 Sep;41(8):714–24.

61. Sanjida S, Janda M, Kissane D, Shaw J, Pearson SA, DiSipio T, Couper J. A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. Psychon. 2016;25(9):1002–16. The paper reviews the use of antidepressants in cancer patients, showing the considerable variation in the prescribing patterns of ADs and the lack of data regarding exact dose or follow-up regimens.

62. Walker J, Hansen CH, Martin P, Symeonides S, Ramessur R, Murray G, Sharpe M. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry. 2014;1(5):343–50. This is a large 3-year study on 21,151 cancer patients who had participated in routine screening for depression in cancer clinics in Scotland, examining both the prevalence of major depression according to the different sites of cancer and the appropriateness of psychiatric treatment.

63. Fisch MJ, Zhao F, Manola J, Miller AH, Pirl WF, Wagner LI. Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors. Psychon. 2015;24(5):523–32. This multi-institutional study enrolled 3106 ambulatory patients with cancer and showed that depressive symptoms were found in nearly half of patients, and one fourth of those with depressive symptoms were taking an antidepressant.

64. Jacob L, Kostev K, Kalder M. Treatment of depression in cancer and non-cancer patients in German neuropsychiatric practices. Psychon. 2016;25(11):1324–8.

65. Fisch MJ, Sherman LK, Adamus AT, Hung FC, Shen LF, Lange GO, Palmer JL. Trends in antidepressant prescribing at a comprehensive cancer center. J Clin Oncol. 2004;22(14suppl):6132.

66. Lal LS, Miller LA, Arbuckle R, Hung F, Feng C, Adamus A, Fisch MJ. Disparities in outpatient antidepressant prescribing patterns and determinants of resource utilization at a tertiary care cancer center. J Support Oncol. 2009;7(6):237–44.

67. Pearson SA, Abramowicz M, Srasuebkul P, Buckley NA. Antidepressant therapy in cancer patients: initiation and factors associated with treatment. Pharmacoeconom Drug Saf. 2015;24(6):600–9.

68. Heron-Speirs HA, Harvey ST, Baken DM. Moderators of psychotherapy effects in people with cancer. Cochrane Database Syst Rev. 2015;1(6):CD011006. General review of the randomized trials of the use of antidepressants in cancer care.

69. Akechi T, Okuyama T, Onishi J, Morita T, Furukawa TA. Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst Rev. 2008 Apr 16;CD005537. doi:10.1002/14651858.CD005537.pub2.

70. Piet J, Würtzen H, Zachariae R. The effect of mindfulness-based oncology therapy effectiveness: meta-analysis of therapy characteristics. J Psychosoc Oncol. 2013;31(6):617–41.

71. Tamagawa R, Garland S, Vaska M, Carlson LE. Who benefits from psychosocial interventions in oncology? A systematic review of psychological moderators of treatment outcome. J Behav Med. 2012;35(6):658–73.

72. Galway K, Black A, Cantwell M, Cardwell CR, Mills M, Donnelly M. Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients. Cochrane Database Syst Rev. 2012 Nov 14;11:CD007064. doi: 10.1002/14651858.CD007064.pub2.

73. Gottlieb BH, Wachala ED. Cancer support groups: a critical review of empirical studies. Psychooncology. 2007;16:379–400.

74. Zimmermann T, Heinrichs N, Baucum DH. “Does one size fit all?” Moderators in psychosocial interventions for breast cancer patients: a meta-analysis. Ann Behav Med. 2007;34:225–39.

75. Manne SL, Andrykowski MA. Are psychological interventions effective and accepted by cancer patients? I. Standards and levels of evidence. Ann Behav Med. 2006;32(2):98–103.

76. Andrykowski MA, Manne SL. Are psychological interventions effective and accepted by cancer patients? II. Using empirically supported therapy guidelines to decide. Ann Behav Med. 2006;32(2):98–103.

77. Breitbart W, Rosenfeld B, Pessin H, Applebaum A, Kulikowski J, Lichtenthal WG. Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer. J Clin Oncol. 2015;33(7):749–55.

78. Lichtenthal WG. Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer. J Clin Oncol. 2015;33(7):749–55. This is the first study showing the efficacy of meaning centered psychotherapy in cancer settings, as a specific intervention to reduce hopelessness and psychosocial suffering in patients with advanced stages of illnesses.

79. Chochovin HM, Kristjanson LJ, Breitbart W, McClement S, Hack TF, Hassard T, Harlos M. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet. 2011;378(9792):753–62.

80. Lo C, Hales S, Chiu A, Panday T, Malaffito C, Jung J, Rydall A, Li M, Nissim R, Zimmermann C, Rodin G. Managing Cancer And Living Meaningfully (CALM): randomised feasibility trial in patients with advanced cancer. BMJ Support Palliat Care. 2016 Jan 19; doi: 10.1136/bmjspcare-2015-000866.

81. Twillman RK, Manetto C. Concurrent psychotherapy and pharmacotherapy in the treatment of depression and anxiety in cancer patients. Psychooncology. 1998;7(4):285–90.

82. Hart SL, Hoyt MA, Diefenbach M, Anderson DR, Kilbourn KM, Cuff J, Steel JL, Cuipers P, Mohr DC, Berendsen M, Spring B, Stanton AL. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst. 2012;104(13):990–1004.
88. Strong V, Waters R, Hibberd C, Murray G, Wall L, Walker J, et al. Management of depression for people with cancer (SMaRT Oncology 1): a randomised trial. Lancet. 2008;372:40–8.
89. Walker J, Sharpe M. Depression care for people with cancer: a collaborative care intervention. Gen Hosp Psychiatry. 2009;31: 436–41.
90. Duarte A, Walker J, Walker S, Richardson G, Holm Hansen C, Martin P, et al. Cost-effectiveness of integrated collaborative care for comorbid major depression in patients with cancer. J Psychosom Res. 2015;79(6):465–70.
91. Sharpe M, Walker J, Holm Hansen C, Martin P, Symeonides S, Gourley C, et al. Integrated collaborative care for major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial. Lancet. 2014;384(9948):1099–108. This extremely well-performed RCT suggests that a specific depression care as a manualised, multicomponent collaborative care treatment that is delivered systematically by a team of cancer nurses and psychiatrists in collaboration with primary care physicians is an effective treatment for major depression in patients with cancer, and it offers a model for the treatment of depression comorbid with other medical condition.
92. Walker J, Hansen CH, Martin P, Symeonides S, Gourley C, Wall L, Weller D, Murray G, Sharpe M, SMaRT (Symptom Management Research Trials) Oncology-3 Team. Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. Lancet Oncol. 2014;15(10):1168–76.
93. Li M, Kennedy EB, Byrne N, Gérin-Lajoie C, Katz MR, Keshavarz H, Sellick S, Green E. Management of depression in patients with cancer: a clinical practice guideline. J Oncol Pract. 2016;12(8):747–56. The report updates the Cancer Care Ontario Program in Evidence-Based Care guideline for the management of depression in adult patients with cancer by covering pharmacologic, psychological, and collaborative care interventions, with a focus on integrating practical management tools to assist clinicians in delivering appropriate treatments for depression in patients with cancer.
94. Li M, Kennedy EB, Byrne N, Gérin-Lajoie C, Katz MR, Keshavarz H, Sellick S, Green E. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psychooncology. 2016; doi:10.1002/pon.4286. The review shows that collaborative care interventions have emerged as multidisciplinary care delivery models, resulting in more long-term depression remission.
95. Moussavi S, Chatterji S, Verdes E, Lopez AD, Mathers D, Ezzati M, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007 Sep 8;370(9590):851–8.
96. Howell D, Keshavarz H, Esplin MJ, Hack T, Hamel M, Howes J, et al. on behalf of the Cancer Journey Advisory Group of the Canadian Partnership Against Cancer. A Pan Canadian Practice Guideline: Screening, Assessment and Care of Psychosocial Distress (Depression, Anxiety) in Adults with Cancer. Toronto: Canadian Partnership Against Cancer (Cancer Journey Advisory Group) and the Canadian Association of Psychosocial Oncology, July 2015.
97. Rayner L, Price A, Hotopf M, Higginson IJ. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer. 2011;47:702–12.
98. Butow P, Price MA, Shaw JM, Turner J, Clayton JM, Grimison P, et al. Clinical pathway for the screening, assessment and management of anxiety and depression in adult cancer patients: Australian guidelines. Psychooncology. 2015;24(9):987–1001.
99. Andersen BL, DeRubeis RJ, Berman BS, Gruman J, Champion VL, Massie MJ, et al. American Society of Clinical Oncology: screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol. 2014;32(15):1605–19.
100. Caruso R, Nanni MG, Riha MB, Sabato S, Grassi L. The burden of psychosocial morbidity related to cancer: patient and family issues. Int’l Rev Psychiatry. (in press)
101. Rubin G, Berendsen A, Crawford SM, Dommett R, Earle C, Emery J, et al. The expanding role of primary care in cancer control. Lancet Oncol. 2015;16:1231–72.
102. Wein S, Sulkes A, Stember S. The oncologist’s role in managing depression, anxiety, and demoralization with advanced cancer. Cancer J. 2010;16:493–9.
103. Hewitt M, Rowland JH. Mental health service use among adult cancer survivors: analyses of the National Health Interview Survey. J Clin Oncol. 2002;20:4581–90.
104. Kadan-Lottick NS, Vanderwerker LC, Block SD, Zhang B, Prigerson HG. Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study. Cancer. 2005;104:2872–81.
105. Keszte J, Danker H, Dietz A, Meister E, Pabst F, Gunin-Lichius O, Oenken J, Singer S, Meyer A. Course of psychiatric comorbidity and utilization of mental health care after laryngeal cancer: a prospective cohort study. Eur Arch Otorhinolaryngol. 2017;274(3):1591-9.
106. Kaul S, Avila JC, Mutambudzi M, Russell H, Kirchhoff AC, Schwartz CL. Mental distress and health care use among survivors of adolescent and young adult cancer: a cross-sectional analysis of the National Health Interview Survey. Cancer. 2017;123(5):869-78.
107. Whitney RL, Bell JF, Bold RJ, Joseph JG. Mental health needs and service use in a national sample of adult cancer survivors in the USA: does psychosocial care improved? Psychooncology. 2015;24(1):80–8.
108. Grassi L, Watson M, IPOS Federation of Psycho-Oncology Societies’ co-authors. Psychosocial care in cancer: an overview of psychosocial programmes and cancer national plans of countries within the International Federation of Psycho-Oncology Societies. Psychooncology. 2012;21(10):1027–33.
109. Grassi L, Fujisawa D, Odyio P, Asuzu C, Ashley L, Bulz B, Travado L, Fielding R, IPOS Federation of Psycho-oncology Societies’ coauthors. Disparities in psychosocial cancer care: a report from the International Federation of Psycho-oncology Societies. Psychooncology. 2016;25(10):1127–13. This is a study examining the problems and obstacles in delivering psychosocial care for cancer patients in the countries worldwide in which a national psycho-oncology society had been established, confirming the disparities and inequalities of psychosocial intervention available in cancer settings.